Gene:
DRD1
dopamine receptor D1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs11746641 10073A>C, 174866091T>G, 19677364T>G
T > G
Not Available
No VIP available No Clinical Annotations available VA
rs11749035 174883052C>T, 19694325C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs2168631 162C>T, 174876002G>A, 19687275G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs265976 174862420G>T, 19673693G>T
G > T
Not Available
No VIP available No Clinical Annotations available VA
rs265981 -684T>C, 174870902A>G, 19682175A>G, 5262T>C
A > G
5' UTR
No VIP available CA VA
rs4532 -48G>A, 174870150C>T, 19681423C>T, 6014G>A
C > T
5' UTR
No VIP available No Clinical Annotations available VA
rs686 *62C>T, 174868700G>A, 19679973G>A, 7464C>T
G > A
3' UTR
No VIP available No Clinical Annotations available VA
rs7725278 174760947T>C, 19572220T>C
T > C
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA147

Details

Cytogenetic Location: chr5 : q35.1 - q35.2
GP mRNA Boundary: chr5 : 174867675 - 174871163
GP Gene Boundary: chr5 : 174864675 - 174881163
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics
    Representation of genes involved in nicotine effects in dopaminergic neurons.

External Pathways

Links to non-PharmGKB pathways.

  1. regulation of ck1/cdk5 by type 1 glutamate receptors - (BioCarta via Pathway Interaction Database)
No related genes are available

Curated Information ?

Curated Information ?

Publications related to DRD1: 15

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. Pharmacogenetics and genomics. 2012. Lee Wonho, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsis. The pharmacogenomics journal. 2012. Man M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics. 2011. Hwang Rudi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010. McCarthy Michael J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The pharmacogenomics journal. 2010. Müller D J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clozapine, GABA(B), and the treatment of resistant schizophrenia. Clinical pharmacology and therapeutics. 2009. Daskalakis Z J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics of dopamine receptors and drug addiction: a comprehensive review. Behavioural pharmacology. 2009. Le Foll Bernard, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature genetics. 2008. Allen Nicole C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Significant association of DRD1 with nicotine dependence. Human genetics. 2008. Huang Weihua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arteriosclerosis, thrombosis, and vascular biology. 2007. Mogi Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. Journal of psychopharmacology (Oxford, England). 2007. Hwang Rudi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in schizophrenia: the quest for individualized therapy. Human molecular genetics. 2002. Basile Vincenzo S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cocaine affects the dynamics of cytoskeletal proteins via sigma(1) receptors. Trends in pharmacological sciences. 2001. Su T P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Scanning of the dopamine D1 and D5 receptor genes by REF in neuropsychiatric patients reveals a novel missense change at a highly conserved amino acid. American journal of medical genetics. 1998. Feng J, et al. PubMed

LinkOuts

Entrez Gene:
1812
OMIM:
126449
UCSC Genome Browser:
NM_000794
RefSeq RNA:
NM_000794
RefSeq Protein:
NP_000785
RefSeq DNA:
AC_000048
AC_000137
NC_000005
NG_011802
NT_023133
NW_001838954
NW_922784
UniProtKB:
DRD1_HUMAN (P21728)
Ensembl:
ENSG00000184845
GenAtlas:
DRD1
GeneCard:
DRD1
MutDB:
DRD1
ALFRED:
LO000275O
HuGE:
DRD1
Comparative Toxicogenomics Database:
1812
ModBase:
P21728
IUPHAR Receptor:
D1 (214)
HGNC:
3020

Common Searches